Arnon Nagler

Dept of Bone Marrow Transplantation, Tel-Aviv University, Israel

Arnon Nagler

Academic positions:
- Director of Hematology Division
- Director, Bone Marrow Transplantation Dept. and Cord Blood Bank, Sheba Medical Center

All industry positions (in last five years):

Research interests:
- Cord blood biology.
- Adoptive cell mediated immunotherapy
- NK and CTL activity.
- Transplantation in hemato-oncological malignancies
- Fibrotic disorders and the role of collagen type I

Any other information:
Associations:
American Society of Hematology
International Society of Experimental Hematology
International Society of Hematology
International Bone Marrow Transplant Registry
European Bone Marrow Transplantation
The International Cord Blood Society
Eurocord: European Cord Blood Transplantation Research Project
The International society for hematotherapy and graft engineering
EORTC Invasive Fungal Infections Cooperative Group
Israel Society of Hematology
Israel Society of Experimental Hematology
Israel Medical Association

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Hematology > Leukemia & Proliferative Disorders of Hematic Cells (since 14 December 2006)

All recent recommendations

• 4.8
  Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
  Recommended by Arnon Nagler, Francesco Onida with Giorgia Saporiti
  
• 4.8
  Concealment of information in clinical practice: is lying less stressful than telling the truth?
  Recommended by Arnon Nagler, Toby Campbell
  
• 6.5
  Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study.
  Recommended by Paolo Rebulla, Arnon Nagler, Ignazio Majolino
  
• 3.0
  Relevance of C1 and C2 epitopes for hemopoietic stem cell transplantation: role for sequential acquisition of HLA-C-specific inhibitory killer Ig-like receptor.
  Recommended by Arnon Nagler
  
• 3.0
  Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia.
  Recommended by Arnon Nagler
  
• 3.0
  Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning.
  Recommended by Arnon Nagler
  
• 3.0
  A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells.
  Recommended by Arnon Nagler